Kyowa Kirin International (KKI), a subsidiary of Japanese pharmaceutical company Kyowa Kirin Co Ltd (TSE:4151), and the University Hospitals Birmingham NHS Foundation Trust on Wednesday announced new real-world data from the global PROCLIPI registry showing meaningful overall survival benefits for patients with advanced mycosis fungoides (MF) and Sézary syndrome (SS), two rare conditions and subtypes of cutaneous T-cell lymphoma (CTCL), who were treated with POTELIGEO (mogamulizumab).

The results were presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting in Athens, Greece.

In the analysis of 371 patients, those receiving mogamulizumab had a median overall survival of 64 months compared to 54 months for patients not receiving the therapy. Among patients with SS, median survival reached approximately 6.5 years with mogamulizumab versus 3 years for systemic treatment without it. These findings align with earlier studies indicating a survival advantage across risk groups.

The PROCLIPI study, spanning 19 countries and more than 2,000 patients, is one of the largest international registries for cutaneous T-cell lymphoma and aims to develop refined prognostic indices such as the new Cutaneous Lymphoma International Prognostic Index (CLIPI).

Kyowa Kirin stated that the results reinforce the value of global collaboration in advancing understanding of rare cancers and improving patient care outcomes in cutaneous T-cell lymphoma.